From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q1 2023 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了公司最近从“需要说服买家考虑”转变为“已进入买家采购、报销、配方、规格、采购、网络、目录或计划系统的批准、指定、上市、合格、注册、报销或预授权选择”,从而使得未来业务的一部分可以在没有每次单独销售事件的情况下到达,并且管理层传达这种准入状态是新的,以至于它带来的大部分数量仍在前方。 在记录中,管理层讨论了在关键能源基础设施市场和非油气工业市场的进展。他们提到“继续获得来自制造该细分市场热力设备的OEM的订单”,以及“在2022年实现了近三位数的同比增长”,并提到“在2023年可能以几乎相同的速度重复同比增长”。他们提到“新业务和重复业务”以及“作为传统老牌企业的替代方案”。然而,这些描述似乎只是普通的销售关系、客户赢得和重复订单,并没有明确提到公司被列入批准供应商名单、规格、目录或类似系统。管理层提到“我们继续寻找机会扩大我们的收入”,但未具体说明公司被纳入任何买方系统。 在非油气市场,他们提到“在2022年实现了超过400%的同比增长”,并提到“重复订单”和“被邀请评估升级”,但同样没有明确提到被纳入系统。 关于“最近跨越”这一点,管理层没有明确说公司最近从候选者转变为默认选择。他们提到“我们相信我们的成功、业绩和记录将使我们能够利用我们的项目清单和能力”,但这是未来展望,不是已实现的状态。 因此,根据提供的记录,管理层没有描述公司被纳入买方系统(如批准供应商名单、规格等)的具体情况。他们描述的是普通的销售关系和客户赢得,每个订单仍需单独说服。因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.